Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5117882 | 0.89 | CNR1 (0.34) | LMNACNR1CNR2 | |
| SCHEMBL5119728 | 0.89 | LMNA (0.31) | LMNA | |
| SCHEMBL5110428 | 0.88 | LMNA (0.40) | LMNATP53TDP1GAAMEN1 | |
| SCHEMBL5126502 | 0.88 | KMT2A (0.34) | LMNATP53MEN1KMT2A | |
| SCHEMBL5114099 | 0.87 | SLC2A1 (0.37) | TP53GAAMEN1KMT2AMAPT | |
| SCHEMBL5124690 | 0.86 | LMNA (0.41) | LMNATP53GAAMEN1KMT2A | |
| SCHEMBL5126340 | 0.86 | SMN1; SMN2 (0.30) | LMNA | |
| SCHEMBL5118850 | 0.85 | LMNA (0.42) | LMNAMEN1KMT2A | |
| SCHEMBL5114370 | 0.85 | TSHR (0.31) | MEN1KMT2ATHRBPOLB | |
| SCHEMBL5119291 | 0.85 | SLC2A1 (0.37) | LMNAMEN1KMT2AMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | disclosed |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | LABORATOIRES FOURNIER SA (FR) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | UGT1A1, UGT2B7, UGT1A6 | LMNA 4632/4885TP53 2886/4885TDP1 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.